Treatment of hepatic encephalopathy with non-absorbable antibiotics
- PMID: 1486194
Treatment of hepatic encephalopathy with non-absorbable antibiotics
Abstract
Hepatic encephalopathy represents a well known neuropsychiatric syndrome in patients with either acute or chronic impaired liver function and is characterized by disturbance of consciousness, personality and intellectual capacity, altered neuromuscular activity and electroencephalographic abnormalities. The pathogenesis of the syndrome is still unknown, although important roles are ascribed to circulating gut-derived toxins of nitrogenous origin and to changing in central neurotransmission. Therefore, treatment is aimed to reduce the production and absorption of gut-derived toxins and to modify central neurotransmission balance. Among the different therapeutic approaches proposed for the management of hepatic encephalopathy, antimicrobial agents, alone or in combination with non-absorbable disaccharides, represent an important step, being able to reduce the production and absorption of ammonia, a compound of key importance in the pathogenesis of hepatic encephalopathy.
Similar articles
-
Rifaximin for treatment of hepatic encephalopathy.Ann Pharmacother. 2009 Jan;43(1):77-84. doi: 10.1345/aph.1K436. Epub 2008 Dec 17. Ann Pharmacother. 2009. PMID: 19092143 Review.
-
Hepatic encephalopathy: pathophysiology and emerging therapies.Med Clin North Am. 2009 Jul;93(4):819-36, vii. doi: 10.1016/j.mcna.2009.03.009. Med Clin North Am. 2009. PMID: 19577116 Review.
-
Pharmacotherapy for hepatic encephalopathy.Drugs. 2010 Jun 18;70(9):1131-48. doi: 10.2165/10898630-000000000-00000. Drugs. 2010. PMID: 20518580 Review.
-
The treatment of chronic hepatic encephalopathy.Hepatogastroenterology. 1991 Oct;38(5):377-87. Hepatogastroenterology. 1991. PMID: 1662661 Review.
-
Management of Hepatic Encephalopathy: A Primer.Ann Pharmacother. 2016 Jul;50(7):569-77. doi: 10.1177/1060028016645826. Epub 2016 Apr 28. Ann Pharmacother. 2016. PMID: 27126547 Review.
Cited by
-
Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis.Front Endocrinol (Lausanne). 2023 Jun 19;14:1130689. doi: 10.3389/fendo.2023.1130689. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37404311 Free PMC article. Review.
-
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.Yonsei Med J. 2005 Jun 30;46(3):399-407. doi: 10.3349/ymj.2005.46.3.399. Yonsei Med J. 2005. PMID: 15988813 Free PMC article. Clinical Trial.
-
Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.J Med Microbiol. 2011 Aug;60(Pt 8):1206-1212. doi: 10.1099/jmm.0.028571-0. Epub 2011 Feb 3. J Med Microbiol. 2011. PMID: 21292853 Free PMC article.
-
Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.Drugs. 1995 Mar;49(3):467-84. doi: 10.2165/00003495-199549030-00009. Drugs. 1995. PMID: 7774516 Review.